

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Non-consolidated Financial Results for the Nine Months Ended December 31, 2025 (Under Japanese GAAP)

January 30, 2026

Company name:	Japan Tissue Engineering Co., Ltd.
Stock exchange listings:	Tokyo Stock Exchange
Securities code:	7774
URL:	https://www.jppte.co.jp
Representative:	Kazuto Yamada, President and CEO
Contact:	Akinobu Wakabayashi, Director, Corporate Officer, Head of Strategic Planning Office
TEL:	+81 533-66-2020
Supplementary materials for financial summaries:	Yes
Financial results briefing:	None scheduled

(Amounts less than one million yen are rounded down.)

1. Non-consolidated Financial Results for the nine months ended December 31, 2025 (from April 01, 2025 to December 31, 2025)

(1) Operating results

(% represents the change rate from the previous period)

	Net sales		Operating profit		Ordinary profit		Net profit	
	Million Yen	%	Million Yen	%	Million Yen	%	Million Yen	%
Nine months ended December 31, 2025	1,509	-11.5	-563	—	-552	—	-556	—
December 31, 2024	1,706	-4.4	-331	—	-330	—	-350	—
	Basic earnings per share		Diluted earnings per share					
Nine months ended	Yen		Yen					
December 31, 2025	-13.70		—					
December 31, 2024	-8.62		—					

(Reference) Investment profit (loss) on equity method Fiscal year ending March 2026 - million yen Fiscal year ended March 2025 - million yen

(2) Financial positions

	Total assets	Net assets	Equity to total assets ratio
As of	Million Yen	Million Yen	%
December 31, 2025	5,890	5,268	89.4
March 31, 2025	6,512	5,825	89.4

(Reference) Equity As of December 31, 2025: 5,268 million yen As of March 31, 2025: 5,825 million yen

2. Cash dividends

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	—	0.00	—	0.00	0.00
Fiscal year ending March 31, 2026	—	0.00	—		
Fiscal year ending March 31, 2026 (Forecast)				0.00	0.00

3. Non-consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2026 (from April 01, 2025 to March 31, 2026)

	Net sales		Operating profit		Ordinary profit		Net profit		Basic earnings per share
	Million Yen	%	Million Yen	%	Million Yen	%	Million Yen	%	Yen
Fiscal year ending March 31, 2026	2,210	-10.0	-550	—	-540	—	-540	—	-13.30

(Note) Revisions to full-year forecast during this quarter Yes

* Notes

(1) Adoption of accounting treatment specific to the preparation of quarterly non-consolidated financial statements : None

(2) Changes in accounting policies, Changes in accounting estimates, Retrospective restatement

(i) Changes in accounting policies based on revisions of accounting standard: None

(ii) Changes in accounting policies other than (i): None

(iii) Changes in accounting estimates : None

(iv) Retrospective restatement : None

(3) Number of issued and outstanding shares (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2025	40,610,200 shares
As of March 31, 2025	40,610,200 shares

(ii) Number of treasury shares at the end of the period

As of December 31, 2025	250 shares
As of March 31, 2025	250 shares

(iii) Average number of shares outstanding during the period

Nine months ended December 31, 2025	40,609,950 shares
Nine months ended December 31, 2024	40,609,952 shares

* Financial results are not subject to audit by certified public accountants or audit firms.

※ Notes for using forecasted information and Others

(Notice Regarding Forward-Looking Statements)

The forward-looking statements, including performance forecasts, contained in this document are based on information currently available to the company and certain assumptions deemed reasonable. They are not guarantees of future performance. Actual performance may differ significantly due to various factors.

Japan Tissue Engineering Co., Ltd.
Non-consolidated Financial Statements for 3rd Quarter of FY2025
(April 1, 2025 – December 31, 2025)

(1) Non-consolidated Balance Sheets

(Thousands of yen)

	FY2024 As of March 31, 2025	FY2025 3Q As of December 31, 2025
Assets		
Current assets		
Cash and deposits	3,885,449	3,335,585
Notes and accounts receivable - trade	543,573	355,180
Electronically recorded monetary claims - operating	50,625	26,970
Merchandise and finished goods	1,928	-
Work in process	17,142	18,937
Raw materials and supplies	162,629	225,555
Other	163,600	166,358
Total current assets	4,824,949	4,128,586
Non-current assets		
Property, plant and equipment		
Buildings, net	608,302	557,704
Land	582,770	582,770
Other, net	229,182	255,748
Total property, plant and equipment	1,420,255	1,396,222
Intangible assets	96,750	99,981
Investments and other assets	171,034	265,919
Total non-current assets	1,688,040	1,762,123
Total assets	6,512,990	5,890,709
Liabilities		
Current liabilities		
Accounts payable - trade	24,890	39,275
Electronically recorded obligations - operating	84,391	60,437
Income taxes payable	21,264	1,865
Provision for bonuses	127,186	61,914
Provision for bonuses for directors (and other officers)	3,397	299
Other	376,099	425,877
Total current liabilities	637,229	589,671
Non-current liabilities		
Provision for retirement benefits	4,725	2,200
Provision for retirement benefits for directors (and other officers)	46,000	30,000
Total non-current liabilities	50,725	32,200
Total liabilities	687,954	621,871
Net assets		
Shareholders' equity		
Share capital	4,958,763	3,997,673
Capital surplus	2,788,763	1,827,673
Retained earnings	-1,922,179	-556,197
Treasury shares	-311	-311
Total shareholders' equity	5,825,035	5,268,838
Total net assets	5,825,035	5,268,838
Total liabilities and net assets	6,512,990	5,890,709

(2) Non-consolidated Statements of Income

(Thousands of yen)

	FY2024 3Q Nine months ended December 31, 2024	FY 2025 3Q Nine months ended December 31, 2025
Net sales	1,706,416	1,509,599
Cost of sales	706,414	674,288
Gross profit	1,000,001	835,310
Selling, general and administrative expenses	1,331,805	1,398,533
Operating loss	-331,803	-563,222
Non-operating income		
Interest and dividend income	1,036	7,646
Income from employees	716	714
Other	564	2,622
Total non-operating income	2,317	10,982
Non-operating expenses		
Foreign exchange losses	579	462
Loss on retirement of non-current assets	0	117
Consumption tax Adjustment	77	119
Other	0	-
Total non-operating expenses	656	699
Ordinary loss	-330,142	-552,939
Loss before income taxes	-330,142	-552,939
Income taxes - current	19,909	3,258
Total income taxes	19,909	3,258
Loss	-350,051	-556,197

(3) Segment Information

I. FY2024 (April 1, 2024 – December 31, 2024)

(Unit: Thousands of yen)

	Reportable segments				Reconciling items	Per financial statements (cumulative)
	Regenerative Medicine Business	Custom Development and Manufacturing Business	LabCyte Business	Reportable segments		
Sales						
Revenues from external customers	1,056,264	477,813	172,337	1,706,416	—	1,706,416
Transactions with other segments	—	—	—	—	—	—
Net sales	1,056,264	477,813	172,337	1,706,416	—	1,706,416
Operating profit (loss)	109,539	243,104	48,673	401,317	-733,121	-331,803

II. FY2025 (April 1, 2025 – December 31, 2025)

(Unit: Thousands of yen)

	Reportable segments				Reconciling items	Per quarterly financial statements (cumulative)
	Regenerative Medicine Business	Custom Development and Manufacturing Business		LabCyte Business		
Sales						
Revenues from external customers	955,904	346,424		207,270	1,509,599	—
Transactions with other segments	—	—		—	—	—
Net sales	955,904	346,424		207,270	1,509,599	—
Operating profit (loss)	5,826	185,622		46,349	237,798	-801,020